Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
molaxole
viatris healthcare limited - macrogol, associazioni - macrogol, associazioni
Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
allespray
viatris healthcare limited - azelastina - azelastina
Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
dymista
viatris healthcare limited - fluticasone, associazioni - fluticasone, associazioni
Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
dygaro
viatris healthcare limited - fluticasone, associazioni - fluticasone, associazioni
Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
acnatac
viatris healthcare limited - clindamicina, associazioni - clindamicina, associazioni
Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
astepro
viatris healthcare limited - azelastina - azelastina
Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
minitran
viatris healthcare limited - nitroglicerina - nitroglicerina
Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
creonipe
viatris healthcare limited - multienzimi (lipasi, proteasi ecc.) - multienzimi (lipasi, proteasi ecc.)
Uni Eropa -
Italia -
EMA (European Medicines Agency)
pirfenidone viatris
viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosoppressori - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).
Uni Eropa -
Italia -
EMA (European Medicines Agency)
dapagliflozin viatris
viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - farmaci usati nel diabete - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.